Apnimed, Inc.

APMD

Apnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024. Insiders bought in the last twelve months.

17.76 0.49 −2.68%
Market cap
$759.6M
P/E
0.9×
Fwd P/E
5.0×
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
0.00
Dividend safety
n/a
Older periods Jun '25 Dec '25 Mar '26 Jun '26
ROE

+1 more TTM period

— — — 0.00%
ROA
— — — 0.00%
ROIC
— 0.00% 0.00% 0.00%
Return on Tangible Assets
— 0.00% 0.00% 64.01%
Average Days of Receivables
— 0.00 0.00 2.15
Free Cash Flow per Share
0.00 — 0.00 (17.46)
Free Cash Flow
— — — (83.75)
Other line items
Cash ROIC
— 0.00% 0.00% (109.87%)
Accounts Receivable Turnover
— — — 0.00
Accounts Payable Turnover
— — — 0.00
Inventory Turnover
— — — 0.00
Average Days of Payables
— 0.00 0.00 375.65
Days of Inventory on Hand
— — — 0.00
Tax Rate
— — — 0.00
Research and Development Expense of Revenue
— — — 49.03%
Selling, General and Administrative Expense of Revenue
— — — 25.61%
Share Based Compensation of Revenue
— — — 3.23%
Operating CF/Net income
— — — (0.88)
Depreciation/Fixed assets
— 0.00 0.00 0.49
Capex/Depreciation
— — — 0.00
Revenue per Share
0.00 — 0.00 24.42
Operating CF per Share
0.00 — 0.00 (17.46)
Capex per Share
0.00 — 0.00 0.00
Capex to Sales
— — — 0.00

Fold the line items

Columns are period end dates · fundamentals updated 7 Oct 2026